中国普通外科杂志2017，Vol.26Issue(11)：1460-1465,6.DOI:10.3978/j.issn.1005-6947.2017.11.014
原发灶激素受体阴性腋淋巴结转移灶激素受体阳性乳腺癌患者的内分泌治疗
Efficacy of endocrinotherapy in breast cancer patients with hormone receptor negative primary lesion and positive axillary lymph node metastasis
摘要
Abstract
Objective: To investigate the clinical efficacy of endocrinotherapy in treatment of breast cancer patients with hormone receptor (HR)-negative primary lesion and HR-positive axillary lymph node metastases.Methods: Sixty-seven breast cancer patients with HR-negative primary lesion and HR-positive axillary lymph node metastases admitted from January 2011 to January 2016 were randomly designated to observation group (33 cases) and control group (34 cases). Patients in both groups received the same chemoradiotherapy regimen, while those in observation group were additionally given administration of tamoxifen (pre-menopausal patients) or letrozole (post-menopausal patients) after chemotherapy. The recurrence/metastasis and survival rates of the two groups of patients were compared. Results: All patients were followed up for 12 to 60 months, during which time, recurrence/metastasis occurred in 13 cases and death occurred in 7 cases in observation group, and recurrence/metastasis occurred in 19 cases and death occurred in 15 cases in control group. The incidence of recurrence/metastasis of the two groups showed no significant difference (P>0.05), while the rate of death due to recurrence/metastasis was significantly lower in observation group than that in control group (P<0.05). The 1-, 3- and 5-year disease-free survival (DFS) rate was 100%, 81.8% and 72.7% in observation group and was 100%, 58.8% and 47.1% in control group respectively; the 1-, 3- and 5-year overall survival (OS) rate was 100%, 90.9% and 81.8% in observation group and was 100%, 70.6% and 58.8% in control group. Both 3- and 5-year DFS and OS in observation group were significantly higher than those in control group (all P<0.05). Conclusion: Attention should be paid to the molecular classification of primary lesion and axillary lymph node metastasis in breast cancer patients. Postoperative endocrinotherapy may improve the survival and reduce the risk of death for breast cancer patients with HR-negative primary lesion and HR-positive axillary lymph node metastases.关键词
乳腺肿瘤/激素拮抗药/无病生存Key words
Breast Neoplasms/Hormone Antagonists/Disease-Free Survival分类
医药卫生引用本文复制引用
郑向欣,柏建印,管小青,吴骥,顾书成,江小玲,侍孝红,袁牧,陆柏林,邱兴,张旭旭..原发灶激素受体阴性腋淋巴结转移灶激素受体阳性乳腺癌患者的内分泌治疗[J].中国普通外科杂志,2017,26(11):1460-1465,6.基金项目
江苏省青年医学人才基金资助项目(QNRC2016490) （QNRC2016490）
江苏省宿迁市社会发展科技基金资助项目(S201610). （S201610）
